drugset / Trial / NCT02333565
Combination of Everolimus and Octreotide LAR in Aggressive Recurrent Meningiomas
NaSingle-groupOpen-labelTreatment
Summary
To determine if combination of everolimus and octreotide exert an anti-tumoral activity in recurrent and/or aggressive meningiomas growth with limited adverse effects.
Timeline
- Start
- 2015-01-22
- Primary completion
- 2019-01-21
- Completion
- 2023-05-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Everolimus | Small molecule | — | — |
| Subject | Octreotide | Peptide | — | — |